

PROVINCIAL FUNDING SUMMARY

Nivolumab (Opdivo) for Metastatic Non-Small Cell Lung Cancer (pCODR 10069)

pERC Recommendation: Recommends with conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: June 20, 2016

This information is current as of October 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Mar 1, 2017	Advanced non-small cell lung cancer, irrespective of histology. Second- or third-line therapy for disease progression on or after prior platinum-based chemotherapy. Patients are eligible to receive nivolumab or pembrolizumab, but not sequential use of these agents. Good performance status, Adequate hepatic and renal function, Access to a treatment centre with expertise to manage immune-mediated adverse reactions of nivolumab. BC Cancer Agency Compassionate Access Program (CAP) approval must be obtained.
AB	Funded	Apr 3, 2017	Criteria Updated: Nivolumab monotherapy for the treatment of patients with advanced or metastatic non-small lung cancer (NSCLC) who progressed on or after cytotoxic chemotherapy Patients previously treated with durvalumab in the adjuvant setting who have relapses after the completion of adjuvant therapy must have had at least a six month interval off durvalumab with no disease recurrence while on durvalumab.
SK	Funded	Mar 23, 2017	As a treatment for adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression on or after cytotoxic chemotherapy for advanced disease and have a good performance status.
MB	Funded	Mar 13, 2017	For the treatment of patients with: Advanced or metastatic non-small cell lung cancer with disease progression on or after cytotoxic chemotherapy for advanced disease AND An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less Patients with EGFR mutation positive non-small cell lung cancer: disease progression must have occurred on or after cytotoxic chemotherapy

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
			AND an EGFR inhibitor Patients with ALK mutation positive non-small cell lung cancer: disease progression must have occurred on or after cytotoxic chemotherapy AND an ALK inhibitor.
ON	Funded	Mar 21, 2017	Treatment for adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression on or after cytotoxic chemotherapy for advanced disease and have a good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity.
NS	Funded	Apr 1, 2017	As a single agent treatment option for patients with advanced or metastatic NSCLC with disease progression on or after cytotoxic chemotherapy for advanced disease. Patients should have a good performance status. Treatment duration should continue until unacceptable toxicity or disease progression.
NB	Funded	May 2, 2017	For the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression on or after cytotoxic chemotherapy for advanced disease who have a good performance status. Treatment should be discontinued upon disease progression or unacceptable toxicity.
NL	Funded	Aug 3, 2017	Patients with advanced or metastatic non-small cell lung cancer with disease progression on or after cytotoxic chemotherapy for advanced disease and have a good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity.
PEI	Funded	Aug 1, 2018	For the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression on or after cytotoxic chemotherapy for advanced disease who have a good performance status.